Cargando…

Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia

INTRODUCTION: Severe hypoglycemia is a medical emergency that must be treated promptly in order to prevent complications or death in a patient. Patients who have been diagnosed with Type 1 diabetes and treated with insulin have the potential to experience a severe hypoglycemia episode, or low blood...

Descripción completa

Detalles Bibliográficos
Autor principal: Schaumleffel, Carol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473428/
https://www.ncbi.nlm.nih.gov/pubmed/37663896
http://dx.doi.org/10.2147/PPA.S325865
_version_ 1785100271420964864
author Schaumleffel, Carol
author_facet Schaumleffel, Carol
author_sort Schaumleffel, Carol
collection PubMed
description INTRODUCTION: Severe hypoglycemia is a medical emergency that must be treated promptly in order to prevent complications or death in a patient. Patients who have been diagnosed with Type 1 diabetes and treated with insulin have the potential to experience a severe hypoglycemia episode, or low blood sugar. When a patient is experiencing severe hypoglycemia, it is imperative for this patient to receive glucose quickly. However, patients who are experiencing low blood sugar may not be able to manage for themselves, take food or liquid orally or may be unconscious. Glucagon is a medication that reverses low blood sugar. Up until 2018, glucagon had to be reconstituted immediately before injection because of the medication’s lack of stability after reconstitution. A medication recently approved for patients 6 years through adult is Dasiglucagon. This form of glucagon comes in a ready-to-administer, pre-filled syringe, making it easier for caretakers and bystanders to administer in an emergency situation due to the readiness of the medication. PURPOSE: The purpose of the paper is to evaluate literature that pertains to the ease of use and patient safety of dasiglucagon HypoPal autoinjector for the management of severe hypoglycemia.
format Online
Article
Text
id pubmed-10473428
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104734282023-09-02 Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia Schaumleffel, Carol Patient Prefer Adherence Review INTRODUCTION: Severe hypoglycemia is a medical emergency that must be treated promptly in order to prevent complications or death in a patient. Patients who have been diagnosed with Type 1 diabetes and treated with insulin have the potential to experience a severe hypoglycemia episode, or low blood sugar. When a patient is experiencing severe hypoglycemia, it is imperative for this patient to receive glucose quickly. However, patients who are experiencing low blood sugar may not be able to manage for themselves, take food or liquid orally or may be unconscious. Glucagon is a medication that reverses low blood sugar. Up until 2018, glucagon had to be reconstituted immediately before injection because of the medication’s lack of stability after reconstitution. A medication recently approved for patients 6 years through adult is Dasiglucagon. This form of glucagon comes in a ready-to-administer, pre-filled syringe, making it easier for caretakers and bystanders to administer in an emergency situation due to the readiness of the medication. PURPOSE: The purpose of the paper is to evaluate literature that pertains to the ease of use and patient safety of dasiglucagon HypoPal autoinjector for the management of severe hypoglycemia. Dove 2023-08-28 /pmc/articles/PMC10473428/ /pubmed/37663896 http://dx.doi.org/10.2147/PPA.S325865 Text en © 2023 Schaumleffel. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Schaumleffel, Carol
Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia
title Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia
title_full Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia
title_fullStr Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia
title_full_unstemmed Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia
title_short Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia
title_sort evaluating ease of use and patient safety of dasiglucagon hypo pal autoinjector for the management of hypoglycemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473428/
https://www.ncbi.nlm.nih.gov/pubmed/37663896
http://dx.doi.org/10.2147/PPA.S325865
work_keys_str_mv AT schaumleffelcarol evaluatingeaseofuseandpatientsafetyofdasiglucagonhypopalautoinjectorforthemanagementofhypoglycemia